Partial response to pralsetinib in an advanced pulmonary sarcomatoid carcinoma patient harboring a KIF5B-RET rearrangement: a case report
Abstract Background Pulmonary sarcomatoid carcinoma (PSC) is a rare and unconventional non-small-cell lung cancer (NSCLC) that appears to be aggressive, with a poor prognosis and response to conventional treatment. Approximately 30% of PSCs have potentially targetable genomic alterations, but few st...
| Auteurs principaux: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Langue: | English |
| Publié: |
BMC
2022-12-01
|
| Collection: | World Journal of Surgical Oncology |
| Sujets: | |
| Accès en ligne: | https://doi.org/10.1186/s12957-022-02848-z |